Product Description
Mechanisms of Action: FIX Analogue
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Chile | Colombia | Croatia | Denmark | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | Indonesia | Italy | Malaysia | Mexico | Netherlands | New Zealand | Norway | Philippines | Spain | Taiwan | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Hemophilia B|Hemophilia A
Phase 2: Multiple Myeloma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01154231 |
3090X1-4415 | N/A |
Completed |
Hemophilia B |
2014-08-29 |
2025-07-17 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments |
|
2004-002648-88 |
Basophil Clinical Study | N/A |
Completed |
Hemophilia B |
2010-01-06 |
2025-05-23 |
Treatments |
|
2015-003027-61 |
2015-003027-61 | P1 |
Active, not recruiting |
Unknown |
2017-04-01 |
2025-06-29 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
ACTRN12620000490976p |
FMTN-II-GIST | P2 |
Not yet recruiting |
Multiple Myeloma |
2022-08-01 |
|||
2008-002037-67 |
2008-002037-67 | P2 |
Completed |
Unknown |
2008-10-14 |
2022-03-12 |
Treatments |
|
2014-004156-65 |
2014-004156-65 | P3 |
Unknown status |
Hemophilia B |
2022-02-02 |
2025-07-02 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
2014-004155-32 |
2014-004155-32 | P3 |
Active, not recruiting |
Hemophilia B |
2018-11-01 |
2025-07-01 |
Primary Completion Date|Start Date|Study Completion Date|Treatments |
|
2011-000520-15 |
Benefix 1010 | P3 |
Completed |
Hemophilia B |
2014-04-24 |
2022-03-13 |
Treatments |
|
NCT01335061 |
Fix:c | P3 |
Completed |
Hemophilia A|Hemophilia B |
2014-04-01 |
2019-03-19 |
||
NCT04286412 |
B1821059 | P4 |
Completed |
Hemophilia A|Hemophilia B |
2020-09-24 |
2021-07-31 |
Primary Completion Date|Primary Endpoints|Treatments |
|
2008-006465-85 |
ND | P4 |
Active, not recruiting |
Unknown |
2010-12-17 |
2022-03-13 |
Treatments |
|
2020-004430-38 |
2020-004430-38 | P4 |
Completed |
Hemophilia B |
2011-07-15 |
2025-07-05 |
||
2007-004017-33 |
2007-004017-33 | P4 |
Completed |
Hemophilia B |
2009-01-20 |
2022-03-12 |
Treatments |
|
2017-003902-42 |
GePKHIS | P4 |
Terminated |
Hemophilia B |
None |
2022-03-13 |
Treatments |
|
2016-000765-22 |
2016-000765-22 | P4 |
Unknown status |
Hemophilia B |
None |
2025-07-06 |
Treatments|Trial Status |